CDK4 and neoplasm: As the inhibitors did not cause a full tumor regression, the researchers performed RNA sequencing, which revealed upregulation of the oxidative phosphorylation (OxPhos) pathway in UM resistant to MEKI and tolerant of the CDK4/6 inhibitor.